Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...
The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...
15hon MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
16h
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
IDLProcycling US on MSN21h
Fantastic one-two for Bahrain-Victorious in Valencia: Buitrago wins ahead of Bilbao, Vacek clings to leader’s jerseySantiago Buitrago won the second stage of the Tour of Valencia. The Colombian of Bahrain-Victorious was the strongest after a ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
In a week that started with U.S. President Donald Trump kicking off a trade war and whipping up market volatility ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Leading AI chip stocks got a lift this week from hyperscale cloud computing companies reiterating their hefty data center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback